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Purpose: Most effective antitumor therapies induce tumor cell death. Non-invasive, 
rapid and accurate quantitative imaging of cell death is essential for monitoring early 
response to antitumor therapies. To facilitate this, we previously developed a biocom-
patible necrosis-avid near-infrared fluorescence (NIRF) imaging probe, HQ4, which 
was radiolabeled with 111Indium-chloride (111In-Cl3) via the chelate diethylene triamine 
pentaacetic acid (DTPA), to enable clinical translation. The aim of the present study was 
to evaluate the application of HQ4-DTPA for monitoring tumor cell death induced by 
radiation therapy. Apart from its NIRF and radioactive properties, HQ4-DTPA was also 
tested as a photoacoustic imaging probe to evaluate its performance as a multimodal 
contrast agent for superficial and deep tissue imaging.
Materials and methods: Radiation-induced tumor cell death was examined in a xeno-
graft mouse model of human breast cancer (MCF-7). Tumors were irradiated with three 
fractions of 9 Gy each. HQ4-DTPA was injected intravenously after the last irradiation, 
NIRF and photoacoustic imaging of the tumors were performed at 12, 20, and 40 h after 
injection. Changes in probe accumulation in the tumors were measured in  vivo, and 
ex vivo histological analysis of excised tumors was performed at experimental endpoints. 
In addition, biodistribution of radiolabeled [111In]DTPA-HQ4 was assessed using hybrid 
single-photon emission computed tomography–computed tomography (SPECT–CT) at 
the same time points.
results: In vivo NIRF imaging demonstrated a significant difference in probe accumula-
tion between control and irradiated tumors at all time points after injection. A similar trend 
was observed using in vivo photoacoustic imaging, which was validated by ex vivo tissue 
fluorescence and photoacoustic imaging. Serial quantitative radioactivity measurements 
of probe biodistribution further demonstrated increased probe accumulation in irradiated 
tumors.
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inTrODUcTiOn
The International Agency for Research on Cancer estimated 
that globally in 2012, 14.1 million new patients were diagnosed 
with cancer and that this number will increase to more than 20 
million in 2025 (1). After diagnosis, most patients with solid 
tumors undergo surgery, radiotherapy and/or chemotherapy, and 
may be followed up with alternative treatments. Conventional 
methods for monitoring antitumor treatment response are based 
on anatomical imaging, e.g., X-ray, magnetic resonance imaging 
(MRI) and computed tomography (CT) every 6–8 weeks during 
the course of treatment as described in the Response Evaluation 
Criteria In Solid Tumors (RECIST) (2). Although RECIST 
provides a standardized guideline, assessment of treatment 
efficacy based on gross tumor size alone may be insufficient for 
certain organs and treatments (3). Moreover, volumetric change 
in tumor size based on conventional imaging may be a delayed 
indicator of treatment effectiveness (4), unnecessarily exposing 
patients to the side effects of additional ineffective treatments, 
and postponing treatment adjustment. Thus, there is a need for 
novel imaging methods to assess tumor response early and at a 
cellular/molecular level in order to determine treatment efficacy 
accurately and adjust the therapy based on tumor response (5, 6). 
Ideally, such methods would be non-invasive, clinically practical, 
and have sufficient sensitivity and specificity for tumor cell death 
in real time.
Imaging of treatment-induced tumor necrosis may facilitate 
quantitation of early treatment response in solid tumors as an 
alternative to the conventional radiological volumetric imaging. 
First, antitumor therapies, such as radiation therapy are known 
to induce several forms of tumor cell death that will often lead to 
secondary necrosis (7–9). Second, necrosis is primarily induced 
by external factors that cause physiochemical damage compared 
to apoptosis that can occur in any tissues during normal develop-
ment and cell turnover (10, 11), making necrosis-based imaging 
method suitable to distinguish cell death induced by antitumor 
therapies. Finally, tumor necrosis, secondary to ischemia and 
insufficient vascularization to support a rapidly proliferating 
tumor mass (12), has been positively correlated with the aggres-
siveness of cancer, and, therefore, has been used as a diagnostic 
biomarker for cancer staging (13–18). Thus, exogenous imaging 
contrast agents that specifically bind to necrotic tumor cells 
in vivo could enable accurate determination of treatment effects 
and disease staging, as well as earlier prediction of treatment 
outcomes for solid tumors (19).
Accurate quantification of tissue necrosis may have wide 
clinical relevance compared to conventional practice, especially 
in monitoring the efficacy of antitumor therapies at earlier stages. 
Existing necrosis-based imaging agents can be divided into two 
general groups: (1) MRI and CT contrast agents that enhance 
endogenous tissue necrosis contrast non-specifically by enabling 
visualization of the presence of an avascular necrotic core and 
(2) positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) contrast agents that 
are specifically targeted to endogenous necrotic tissue (8, 13–18, 
20–29). Non-specific tissue necrosis-imaging agents will likely 
fall into abeyance when affordable necrosis-specific agents 
become clinically available. Thus far, only a few agents have 
been considered clinically applicable, including necrosis-avid 
photosensitizer hypericin (Oncocidia™) (30–32) and 131Iodine-
conjugated Tumor Necrosis Targeting monoclonal antibody 
(TNT-3, Peregrine Pharmaceuticals, CA, USA) (24, 33). While 
clinical feasibility has been shown for both agents (34), several 
drawbacks may hinder their wide-spread clinical adoption (27, 
30, 35–37). For example, hypericin is phototoxic, poorly soluble, 
and aggregates rapidly. Monoclonal antibodies are relatively large 
in size, have long circulation times, may induce host immune 
response, and are expensive to develop using good manufactur-
ing practices (GMP) (35–38).
Recognizing the biological significance of tumor necrosis 
as a hallmark of tumor response to treatment and the need for 
alternative imaging methods to measure treatment-induced 
solid tumor necrosis, we previously developed a biocompatible 
near-infrared fluorescence (NIRF), water-soluble imaging probe 
called HQ4. HQ4 is economical to produce, is non-phototoxic, 
and binds specifically to cells with compromised cell membrane 
integrity (38). We validated HQ4-diethylene triamine pentaacetic 
acid (HQ4-DTPA) as a necrosis-avid contrast agent histologically 
by demonstrating localization of HQ4-DTPA in necrotic tumors, 
and indicated that HQ4-DTPA could be made more clinically 
practical by addition of a radioactive moiety (38). Building on 
these results, in the current study, we investigated the utility of 
HQ4-DTPA as a necrosis-imaging agent in vivo to measure tumor 
response to radiation therapy. Since radiotherapy is used to treat 
over 50% of cancer patients (39), the translational value of HQ4-
DTPA is promising.
conclusion: HQ4-DTPA has high specificity for dead cells in vivo, potentiating its use as 
a contrast agent for determining the relative level of tumor cell death following radiation 
therapy using NIRF, photoacoustic imaging and SPECT in vivo. Initial preclinical results 
are promising and indicate the need for further evaluation in larger cohorts. If successful, 
such studies may help develop a new multimodal method for non-invasive and dynamic 
deep tissue imaging of treatment-induced cell death to quantitatively assess therapeutic 
response in patients.
Keywords: radiation therapy, cell death, multimodal imaging, fluorescence imaging, cyanine, necrosis avid 
contrast agent, treatment response, cancer
FigUre 1 | experimental schedule. Three fractions of 9 Gy irradiation were delivered with a 5-h interval and HQ4-DTPA was injected at the end of the irradiation 
schedule. In vivo photoacoustic and fluorescence imaging were performed at 12, 20, and 40 h following the injection.
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In this study, we examined a relatively high-dose-per-fraction 
treatment scheme (3 ×  9  Gy) to induce tumor cell death. This 
regime was calculated based on a biological equivalent dose 
(BED) that is clinically relevant to 60  Gy for 2  Gy fractions, 
given a known α/β ratio of MCF-7 cells, comparable to the aver-
age α/β ratio of humans, and the incomplete repair model. We 
investigated a trimodal HQ4-DTPA imaging (photoacoustic, 
NIRF, SPECT) approach to measure tumor response to radiation 
therapy in a MCF-7 human breast cancer mouse xenograft model. 
We reasoned that the addition of photoacoustic imaging would 
overcome some of the disadvantages associated with SPECT and 
NIRF, such as the exposure to ionizing radiation emitted from 
radionuclides and the limited penetration depth (40), respectively. 
Photoacoustic imaging may also be ideal for routine clinical use 
as it is easily accessible, minimally invasive, and technologically 
inexpensive compared to conventional imaging methods (CT, 
MRI). The results of this work demonstrate the feasibility of using 
the multimodal (NIRF, photoacoustic, SPECT) HQ4-DTPA probe 
in vivo for longitudinal measurement of solid tumor necrosis in 
response to clinically relevant high-dose radiotherapy.
MaTerials anD MeThODs
hQ Preparation
HQ4-DTPA was obtained from Ilumicare BV (Rotterdam, 
The Netherlands). HQ4-DTPA was synthesized as previously 
described (38). For phantom studies, dilutions of HQ4-
DTPA were prepared in phosphate buffered saline (PBS) 
at various concentrations (12.5, 25, 50, and 100  μM). For 
in vivo mouse studies, 100 μL that represents 10 nmol HQ4-
DTPA was injected via the tail vein. To label HQ4-DTPA 
with 111InCl3, HQ4-DTPA was dissolved in 0.1  M HEPES 
(10  μg/100  μL) (41) and incubated with 111InCl3 (35  MBq; 
Nordion, Vancouver, BC, USA). After 30 min of incubation 
on a shaker, labeling was validated with instant thin layer 
chromatography (ITLC). In all cases, labeling efficacy was 
greater than 90%.
cell culture
GFP-fluorescent MCF-7 human breast cancer cells (kindly 
provided by Dr. Shirley Wu, Leslie Dan Faculty of Pharmacy, 
University of Toronto) were grown in DMEM Medium sup-
plemented with 10% fetal bovine serum and 1% Pen-Strep in a 
humidified incubator at 37°C and 5% CO2. Cells were trypsinized, 
counted, and suspended in 10% PBS before further use.
animal studies
All animal procedures were conducted in accordance with 
appropriate regulatory standards under protocols AUP#2407 
and #3004 approved by the University Health Network 
Institutional Animal Care Committee, and conform to the insti-
tutional guidelines for the proper and humane use of animals 
in research. Eight to 10-week-old female athymic nude mice 
(NCRNU-F strain) were obtained from Taconic Biosciences 
(Hudson, NY, USA). Approximately 2 × 106 MCF-7-GFP cells 
were injected subcutaneously in both sides of the mouse scapu-
laris region and were allowed to grow for 3–4 weeks until they 
reached approximately 5  mm in diameter, as measured using 
a caliper. All experimental procedures were conducted under 
isoflurane gas anesthesia (2–3%, 0.8 L/min). All animal experi-
ments were performed following the treatment schedule shown 
in Figure 1. Briefly, pre-treatment images were obtained prior 
to irradiation to determine the size of the tumors based on bulk 
tumor GFP fluorescence. Tumor GFP fluorescence intensity is 
a delayed indicator of tumor response to irradiation since the 
GFP protein has a half-life of ~26 h (42), ergo, GFP fluorescence 
intensity was not used to quantify tumor response following 
irradiation.
radiation Treatment and hQ4-DTPa 
administration
All irradiation procedures were performed using a small animal 
irradiation system (XRad 225Cx, Precision X-Ray Inc., North 
Branford, CT, USA) at a photon energy of 225 kVp and a tube 
current of 13 mA. Tumors were localized using x-ray fluoroscopy 
prior to irradiation. A 1.5  cm circular collimator was used to 
irradiate tumors at a dose rate of 2.9 Gy/min. The dose rate was 
measured using radiochromic films and a solid water phantom, 
as described previously (43). After delivery of the last radiation 
fraction, HQ4-DTPA was injected via the tail vein and anesthe-
tized mice were imaged with each modality at 12, 20, and 40 h 
following injection (Figure 1).
Fluorescence imaging
In vivo and ex vivo fluorescence images of GFP and HQ4-DTPA 
signals in MCF-7 tumors were obtained using the IVIS Spectrum 
imaging system (Perkin Elmer Inc., Waltham, MA, USA). GFP 
fluorescence signal was collected with an excitation wavelength of 
465 nm and an emission wavelength of 500 nm (±20 nm). HQ4-
DTPA NIRF signal was collected with an excitation wavelength of 
675 nm and an emission wavelength of 720 nm (±20 nm).
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Photoacoustic imaging
Tissue phantom, in  vivo and ex vivo photoacoustic imaging of 
MCF-7 tumors was performed using the Vevo LAZR system 
(FujiFilm VisualSonics Inc., Toronto, ON, Canada) with a 
21 MHz center-frequency transducer. To prepare the phantom, 
HQ4-DTPA samples prepared at different concentrations (12.5, 
25, 50, and 100 μM) were passed through polyethylene tubes that 
were placed on a piece of sliced turkey breast, having an approxi-
mate thickness of 2.5 mm. Additional layers of meat were added 
to simulate various thicknesses of tissues. Photoacoustic images 
were obtained after the addition of each layer. For all experiments, 
3D photoacoustic and ultrasound images were acquired simul-
taneously with a single wavelength of 700 nm for HQ4-DTPA, 
and the built-in Spectro mode was used to obtain the absorption 
spectrum from 680 to 900 nm.
sPecT-cT imaging
Mice were imaged at 12, 20, and 40 h after intravenous injection 
of [111In]DTPA-HQ4. Mice were anesthetized by inhalation of 
2% isoflurane in medical grade air. Imaging was performed on 
a nanoSPECT/CT system (Bioscan Inc., Washington, DC, USA) 
with four NaI(Tl) detectors fitted with 1.4-mm multi-pinhole 
collimators (resolution <1.2 mm at full-width-half-maximum). 
Cone beam CT images were acquired first (180 projections, 
45 kVp), followed by the SPECT images. Photons were accepted 
from the 10% window centered on both the 245 keV and 171 keV 
photopeaks of 111In. A total of 24 projections were obtained in 
a 256 ×  256 matrix for a total of 45  min. The CT slices were 
reconstructed using a filtered back-projection algorithm, whereas 
the SPECT slices were reconstructed using an ordered subset 
expectation maximization (OSEM) algorithm with four subsets 
and nine iterations. CT and SPECT images were anatomically 
co-registered using the InVivoScope software (Bioscan/inviCRO, 
Boston, MA, USA).
Three mice were sacrificed after each experimental time point. 
Tissues were excised, weighed, and counted for radioactivity 
(PerkinElmer Wallac 1480 Wizard 3ʺ gamma-counter, Waltham, 
MA, USA) along with a standard of the injected dose, so that the 
decay-corrected uptakes of HQ4-DTPA were determined as the 
percentage of the injected dose per gram (% ID/g). The % ID/g 
was calculated as follows: [(MBq measured in tissue/injected 
dose) × 100%/weight of tissue]. The total injected dose per mouse 
was equal to the difference between the pre- and post-injection 
syringe radioactivity, as measured by a CRC-15R dose calibrator 
(Capintec, Ramsey, NJ, USA).
Ex Vivo Fluorescence imaging and 
autoradiography
Tumors were resected at the experimental endpoints, and were 
either embedded in OCT compound and snap frozen in liquid 
nitrogen, or fixed in formalin. Frozen sections were imaged using 
a phosphor imager (Cyclone Plus, Perkin Elmer) to detect 111In 
radioactivity. The same sections were subsequently imaged to 
measure HQ4-DTPA fluorescence with an excitation wavelength 
of 650  nm using TissueScope system (Huron Technologies). 
Formalin-fixed tissue sections were subjected to Hemotoxylin 
and Eosin (H&E) staining and TdT-mediated dUTP Nick-End 
Labeling (TUNEL) staining (Promega, Madison, WI, USA) to 
detect radiation-induced tumor cell death including necrosis 
(44, 45).
statistical analysis
All statistical analyses were performed using GraphPad Prism® 
software (GraphPad Software, San Diego, CA, USA). Student’s 
t-test was used to compare two sets of data, and two-way repeated 
measures ANOVA with Bonferroni post-test was used for serial 
imaging data. p < 0.05 was considered significant, and error bars 
represent the mean ± SEM.
resUlTs
hQ4-DTPa as a Photoacoustic  
contrast agent
To evaluate the application of HQ4-DTPA in addition to the 
NIRF property that was described previously (38), the photoa-
coustic property of carboxylated cyanine HQ4-DTPA was tested 
in a phantom composed of transparent plastic tubes. As seen in 
Figures 2A,B, HQ4-DTPA absorption increased with increasing 
concentration, demonstrating a peak at around 710 nm excita-
tion. The photoacoustic absorption spectrum was similar to 
its known fluorescence spectrum (38), supporting its use as an 
extrinsic photoacoustic contrast agent.
To further characterize its performance as a photoacoustic 
contrast agent, multiple layers of meat were added over top of 
the tube phantoms to simulate a tissue thickness of up to 1 cm. 
After the addition of each layer of meat, fluorescence and pho-
toacoustic images, as well as photoacoustic absorption spectra, 
were acquired. In this way, we represented similar scattering 
and absorption patterns to those found in the human body. The 
fluorescence signals derived from the different concentrations 
were indistinguishable by the addition of the first layer of turkey 
breast tissue (2.5-mm thick) (data not shown). The photoacoustic 
intensity of the agent in the tubes was, however, detectable with 
layers up to 10 mm in total thickness at the highest concentration 
of HQ4-DTPA (100 μM) (Figure 2C). Figure 2D shows the PA 
absorption spectra of 100 μM HQ4-DTPA with the addition of 
2.5-mm-thick tissue layers.
In Vivo serial Photoacoustic and 
Fluorescence imaging of hQ4-DTPa 
accumulation in irradiated Tumors
TdT-mediated dUTP nick-end labeling staining of irradiated 
tumor demonstrated over a two-fold difference in tumor 
cell death in tumors irradiated with three fractions of 9  Gy 
(27  Gy total), compared to non-irradiated control tumors 
(Figures  3A,B). H&E staining was performed to confirm the 
TUNEL positive area as necrotic. The arrowheads in the image 
mark the difference in H&E staining between healthy and 
necrotic tissue. Based on those results, the same irradiation 
treatment regimen was used for all subsequent experiments. 
FigUre 2 | Photoacoustic property of hQ4-DTPa. (a) Representative ultrasound (top) and photoacoustic (bottom) images of HQ4-DTPA in a tube phantom 
at different concentrations (from left to right: 12.5, 25, 50, and 100 μM). The photoacoustic image was acquired at 700 nm. (B) Corresponding absorption 
spectra of HQ4-DTPA for the different concentrations. (c) Representative ultrasound (top) and photoacoustic (bottom) images of HQ4-DTPA in the same tube 
phantom as in (a), covered with 10-mm-thick meat. The dashed circles indicate the location of tubes, and the solid circle indicates the photoacoustic 
absorption of the tube containing 100 μM HQ4-DTPA. (D) The corresponding absorption spectra of 100 μM HQ4-DTPA with various thicknesses of meat 
covering the tube.
FigUre 3 | histological analysis of cell death after irradiation. (a) Representative images of TUNEL and H&E staining for control and irradiated tumor 
resected 40 h after irradiation. The arrowheads point to necrotic areas. Scale bar = 500 μm. (B) Quantified TUNEL positivity for tumors resected 40 h after 
irradiation, expressed as % positivity (n = 7/group, *p < 0.05).
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FigUre 5 | Ex vivo photoacoustic and fluorescence imaging. 
Representative ultrasound, photoacoustic, GFP fluorescence (FLI-GFP) and 
HQ4-DTPA fluorescence (FLI-HQ4) images of control and irradiated tumors 
resected 40 h after injection of HQ4. Scale bar = 2 mm.
FigUre 4 | In vivo photoacoustic and fluorescence imaging of tumors. (a) Representative photoacoustic images of control and irradiated tumors prior to and 
at 12, 20, and 40 h following injection of HQ4-DTPA. The photoacoustic image was acquired at 700 nm and an accumulation of HQ4-DTPA inside the irradiated 
tumor was observed. Scale bar = 2 mm. (B) Measured photoacoustic intensity at different time points (n = 3/group). (c) Representative fluorescence images of the 
GFP-MCF7 tumor and HQ4-DTPA in control (C) and irradiated (R) tumors. (D) Measured fluorescence intensity of HQ4-DTPA at different time points (n = 10/group, 
*p < 0.05, **p < 0.01).
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As demonstrated in Figure  4A, the photoacoustic images 
demonstrated accumulation of HQ4-DTPA inside the treated 
tumor mass, while some endogenous photoacoustic signals 
were observed in the outer rim of the tumor in both control and 
irradiated tumors. Figure 4B demonstrated a trend for increased 
accumulation of HQ4-DTPA in irradiated tumors compared to 
control tumors, although the difference was not statistically 
significant. The fluorescence images (Figures 4C,D) showed an 
approximate 1.8-fold increase in HQ4-DTPA accumulation in 
the irradiated subcutaneous tumors compared to non-irradiated 
controls, most notably at 12 h post-radiotherapy.
Validation of Photoacoustic and 
Fluorescence imaging of hQ4-DTPa in  
Ex Vivo Tissues
To validate in vivo observations, control and irradiated tumors 
were resected 40 h following injection of HQ4-DTPA and subse-
quently imaged by photoacoustic and fluorescence systems. The 
resected masses were confirmed to be tumors based on the GFP 
fluorescence signal. As seen in Figure 5, increased HQ4-DTPA 
accumulation in an irradiated tumor was observed based on 
photoacoustic and fluorescence images. This indicated that the 
increased accumulation of HQ4-DTPA was specific to radiation-
induced tumor cell necrosis in tumors. Since the skin covering 
the xenografted tumor was removed during resection, there was 
less interference from the intrinsic hemoglobin signal from blood 
vessels in the skin.
FigUre 6 | sPecT-cT of [111in]DTPa-hQ4-DTPa biodistribution. (a) Representative transversal SPECT–CT image of the mouse with control (C) and irradiated 
(R) tumor 40 h following injection. (B) Measurement of [111In]DTPA-HQ4 biodistribution in% ID/weight in different organs at various time points (12, 20, and 40 h post 
injection), where irradiated tumor (“tumor r”) shows higher accumulation of the probe compared to control (“tumor l”) (n = 3, *p < 0.05).
FigUre 7 | Ex vivo fluorescence and autoradiography images of tumors. Representative images of (a) control and (B) irradiated tumor resected 40 h 
following injection of [111In]DTPA-HQ4. The tumors were imaged for HQ4-DTPA fluorescence. (c) Overlay (C3) of HQ4-DTPA fluorescence (C1-red) and 111InCl3 
radioactivity (C2-green) in a tumor, illustrating co-localization of the two signals.
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In Vivo Biodistribution and Ex Vivo 
Validation of 111in radiolabeled hQ4-DTPa
SPECT-CT was performed to quantify whole-body biodistribu-
tion of [111In]DTPA-HQ4 in MCF-7 tumor-bearing mice fol-
lowing the experimental treatment schedule shown in Figure 1. 
Radiolabelling efficiency of HQ4-DTPA was determined to 
be greater than 90%. Significantly higher accumulation of 
[111In]DTPA-HQ4 in irradiated tumors was observed compared 
to controls in the same mice 40 h after probe injection [tumor-
to-background ratio (TBR) = 1.8, p40 h = 0.03] (Figure 6A), thus 
confirming HQ4’s specificity for necrotic tissues and suggesting 
the kinetics of HQ4-DTPA accumulation. Measurements 
of  radioactivity in various resected organs demonstrated that 
[111In]DTPA-HQ4 was concentrated in the excreting organs 
with a peak in the kidneys, suggesting that the renal system 
was the main excreting route (Figure  6B). Lastly, the tumors 
were resected and imaged for [111In]DTPA-HQ4 using auto-
radiography and fluorescence. The autoradiographic images 
revealed a clear difference in structural characteristics between 
the irradiated and control tumors (Figures 7A,B). The internal 
tissue organization of the non-irradiated tumor was cohesive and 
showed a clear cellular pattern with a homogeneous color. By 
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contrast, the irradiated tumor showed a high level of disorganiza-
tion. Furthermore, the overlay (C3) of fluorescence (C1-red) and 
autoradiography (C2-green) images showed a high degree of 
co-localization of 111In-Cl3 and HQ4-DTPA fluorescence signal 
(Figure 7C).
DiscUssiOn
In the current study, we evaluated HQ4-DTPA as a multimodal 
necrosis-avid imaging agent to assess tumor response to a clini-
cally relevant radiotherapy dose using a MCF-7 human breast 
cancer mouse xenograft model. The necrosis-avid property of 
HQ4-DTPA for detection of chemotherapy-induced tumor cell 
necrosis was previously demonstrated using NIRF and SPECT 
(38). To extend the applicability of HQ4-DTPA to another imag-
ing modality, we first assessed its photoacoustic property and 
demonstrated its distinct optical absorption peak at ~700  nm. 
Based on this result, multimodal imaging was performed to 
quantitatively evaluate the in  vivo use of HQ4-DTPA to detect 
tumor response to radiotherapy using a fractionated irradiation 
scheme (3 × 9 Gy). Our in vivo fluorescence results demonstrated 
an increase in HQ4-DTPA signal in irradiated tumors compared 
to non-irradiated tumors in vivo for up to 40 h after treatment, 
indicating specific and sustained accumulation of HQ4-DTPA in 
irradiated tumors. These data were supported by ex vivo NIRF 
and photoacoustic imaging of control and irradiated tumors. 
Lastly, we used SPECT-CT to quantitate the biodistribution of 
HQ4-DTPA, demonstrating HQ4-DTPA accumulation in irradi-
ated tumors and clearance of unbound HQ4-DTPA mostly via 
kidneys, which was visualized at all time points. Collectively, our 
data indicated that HQ4-DTPA may be used as a multimodal 
necrosis-specific imaging agent. The data also suggested that 
HQ4-DTPA may be used clinically in the future to monitor solid 
tumor response to radiation therapy in a practical time frame.
Radiation therapy was selected as the treatment modality for 
the breast cancer model in the present study because of its wide-
spread clinical usage. Breast conserving surgery is the standard 
treatment for localized breast cancer in combination with (neo-)
adjuvant therapies (46), such as radiation therapy, which has 
been shown to reduce local recurrence (47). Radiation therapy is 
commonly administered in a conventional fractionated schedule 
(25 fractions of 2 Gy) on the breast with an additional boost of 
up to 10  Gy on the lumpectomy cavity (47). Since such treat-
ment schemes cannot be easily replicated in a relevant manner in 
animal models, we selected a radiation regimen that is isoeffective 
to a clinically relevant fractionated irradiation regimen based on 
a BED of 60 Gy in 2 Gy fractions (48, 49). Thus, the rationale 
for three fractions of 9 Gy with a 5-h interval was based on the 
BED for 60  Gy, calculated using the α/β ratio of MCF-7 cells 
(4.62) (50, 51) and by taking into account the incomplete repair 
model based on the halftime of recovery from radiation damage 
in murine skin. Although the radiation regimen used in our study 
may not be used routinely or be clinically practical, we assumed 
that the regimen was appropriate to mimic the total radiation 
dose given in cancer patients as the BED is used to compare the 
relative effectiveness of different radiation protocols that vary in 
fraction size.
The NIRF properties of carboxylated cyanine HQ4-DTPA 
and its radioactive labeled variant [111In]DTPA-HQ4 have been 
previously demonstrated by our group (38). Although nuclear 
imaging overcomes the limited tissue penetration depth of NIRF 
imaging (40, 52), it has its drawbacks, including radiation safety, 
cost of radioactive materials, limited temporal sensitivity, and the 
lack of anatomical detail (53). Photoacoustic imaging overcomes 
such limitations and offers a novel and clinically relevant means 
of imaging HQ4-DTPA in  vivo. Since photoacoustic imaging 
includes ultrasound imaging, both anatomical and functional 
information can be obtained simultaneously in real time. 
Photoacoustic imaging can image beyond the depth limitation of 
fluorescence imaging to more than 5 cm (54), making it suitable 
for imaging deeper tumors. In the current in vitro experiments, we 
distinguished a specific photoacoustic signal at a maximum depth 
of 1 cm, achieving five times the tissue depth of NIRF imaging. 
However, depth imaging beyond 1 cm could not be performed 
due to the inherent property of the high-frequency ultrasound 
transducer (21 MHz) used in our study. Photoacoustic imaging 
depth may be increased by using a lower frequency transducer, but 
at the expense of reduced detection sensitivity (55). Alternatively, 
a higher concentration of the probe may facilitate detection in 
deeper tissue.
Despite the advantages of photoacoustic imaging, there are 
some technical limitations. First, photoacoustic imaging may not 
be a suitable method for certain organs, such as lung and brain, 
where acoustic impedance is different between tissue interfaces 
(56). However, several preclinical studies demonstrated the use of 
photoacoustic imaging in these organs, suggesting future use of 
photoacoustic imaging in a variety of organs (57–59). Second, the 
clinical use of photoacoustic contrast must be approached cau-
tiously, since photoacoustic imaging visualizes any tissue-based 
optical absorber at a given wavelength. As such, this method 
detects the presence of endogenous hemoglobin, a primary opti-
cal absorber in tissues, across a broad spectral range that includes 
700–750  nm, corresponding to the peak absorption of HQ4. 
Our photoacoustic imaging results indicated the presence of an 
endogenous optical absorber mostly in the periphery of control 
and irradiated tumors, suggesting the presence of vasculature 
around the tumor. The endogenous absorption limited our ability 
to detect HQ4-DTPA in a highly specific manner. To distinguish 
absorption by any contrast agent from that of endogenous 
absorbers, photoacoustic spectral unmixing techniques can be 
performed to obtain a clear overview of the contrast agent 
signal based on its known spectrum (60). Such techniques can 
be applied in future studies to visualize the accumulation of 
HQ4-DTPA inside the irradiated tumors in a specific manner. 
In addition, the imaging probe may accumulate inside tumors 
due to intrinsic tumor necrosis resulting in the presence of 
background signal in both fluorescence and photoacoustic 
imaging. In such cases, baseline imaging needs to be performed 
with the injection of HQ4-DTPA prior to initiation of an anti-
cancer treatment.
Although NIRF imaging is widely clinically applicable, its 
use as a singular imaging modality to assess biological activities 
may be suboptimal. For example, fluorescence properties of 
exogenous dyes used in vivo are strongly influenced by the tissue 
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microenvironment, such as hydrophobicity and pH, as well as 
by interactions with various proteins (61, 62). Such interactions 
will influence HQ4-DTPA fluorescence intensity differently in an 
in vivo environment of living cells, which may hamper quantifica-
tion of probe accumulation inside necrotic tumors. These same 
interactions may have contributed to the differences in the time 
point of highest signal accumulation observed using the different 
imaging methods in our model, although it was not explicitly 
addressed in this study. To achieve absolute quantification of a 
probe, gamma spectroscopy or mass spectrometry should be 
considered (61, 62). In our study, quantification of HQ4-DTPA 
was achieved by measurement of radioactivity in various organs, 
supporting the in vivo imaging data in a quantitative manner.
Irradiation causes direct DNA damage and the production of 
reactive oxygen species (ROS), both leading to cell death. The 
amount and the type of cell death depend on the tumor type and 
the irradiation dose per fraction. For MCF-7 cells, the α/β ratio, a 
model of radiation effect, is relatively low compared to the higher 
α/β ratios for other tumors, such as Tara-1/2 (teratoma), DU145 
(bladder), TSU, and UNCap (prostate) (e.g., 7–20 Gy) (51), sug-
gesting that the treatment response may be delayed in MCF-7 
tumor-bearing animals. This delayed response can be seen by our 
in vivo radioactivity-based biodistribution results demonstrating 
significant differences of HQ4-DTPA accumulation between the 
treated and control tumor 40 h after irradiation. This discrepancy 
may increase even more over time, requiring re-injection of the 
probe at a later time point or at multiple time points following 
radiotherapy. In addition, radiation-induced damage may be 
more severe when high dose of radiation is used per fraction, 
leading to direct tumor cell destruction as well as secondary tumor 
cell death (63, 64). Therefore, future studies may focus on multi-
fractionated scheme with a lower fraction dose to assess whether 
the proposed necrosis-imaging technique is still applicable. In 
testing multi-fractionation schemes, the imaging technique could 
be initially tested in the same way so immediately after the end of 
the complete treatment, and later on even during the treatment 
process to assess its utility in adapting therapeutic regimen. In 
the current study, we chose to inject HQ4-DTPA immediately 
after the final tumor irradiation to detect early treatment response 
since the goal of this study was to investigate HQ4-DTPA imaging 
as an early indicator of radiation-induced necrosis, Collectively, 
future studies are warranted with multi-fractionation scheme 
and/or injections at multiple time points to evaluate its utility in 
treatment monitoring and adaptive treatment.
Overall, we have demonstrated that HQ4-DTPA can be 
used to objectively assess tumor response to radiation therapy. 
HQ4-DTPA is distinct from current clinically available necrosis-
avid agents given its unique in vivo specificity and multimodal 
imaging capability. The added benefit of multimodal imaging 
potentially broadens its applicability in a variety of clinical 
settings, where tissue necrosis serves as a surrogate marker of 
diseases as well as response to necrosis-inducing treatments. 
The advantages of the small molecule [111In]DTPA-HQ4 include 
high water solubility, the photoacoustic property that enables 
deep tissue penetration into tissues, lack of phototoxicity, and 
low production costs. Unlike fluorescence imaging and SPECT, 
photoacoustic imaging combines the anatomical and functional 
properties of tissue in a 3D image. Therefore, the necrosis avid 
radiotracer [111In]DTPA-HQ4 has the potential to be clinically 
translated for diagnostic and prognostic purposes, as well as to 
predict early treatment outcome of antitumor treatments, such 
as radiation therapy. Additional preclinical and clinical studies 
are required to demonstrate the advantages of this novel imaging 
approach to assess early treatment efficacy and inform adaptive 
therapy decisions for individual patients.
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